Artal Group’s Axsome Therapeutics AXSM Stock Holding History

Artal Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-76,837	Closed	-$6.13M	–	118
2024 Q1	$6.13M	Buy	+76,837	New	+$6.45M	0.16%	58

Other funds holding AXSM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artal Group's AXSM Position: Q2 2024 in Review

Artal Group sold out of Axsome Therapeutics (AXSM) in Q2 2024, closing a stake of 76,837 shares — an estimated $6.13M sold.

Artal Group first reported a position in AXSM in Q1 2024 and held it in 1 quarter. The position peaked at $6.13M in Q1 2024. 256 funds tracked by Wall St. Rank hold AXSM as of Q2 2024.

Artal Group reported no remaining Axsome Therapeutics position as of Q2 2024 after selling out during the quarter.
Artal Group sold 76,837 Axsome Therapeutics shares in Q2 2024, an estimated $6.13M.
Artal Group first reported a position in Axsome Therapeutics in Q1 2024 and held it in 1 quarter.
Artal Group's Axsome Therapeutics position peaked at $6.13M in Q1 2024.
256 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2024.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.